Skip to Content


In the US, Apixaban (apixaban systemic) is a member of the drug class factor Xa inhibitors and is used to treat Deep Vein Thrombosis, Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery, Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Deep Vein Thrombosis - Prophylaxis, Prevention of Thromboembolism in Atrial Fibrillation, Pulmonary Embolism, Thromboembolic Stroke Prophylaxis and Venous Thromboembolism.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Anticoagulant agent: Direct, selective inhibitor of blood-coagulation factor Xa

Chemical Name

1-(4-Metoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (WHO)

Foreign Names

  • Apixabanum (Latin)
  • Apixaban (German)
  • Apixaban (French)
  • Apixabán (Spanish)

Generic Names

  • Apixaban (OS: USAN, JAN, BAN)
  • BMS-562247-01 (IS)
  • UNII-3Z9Y7UWC1J (IS)

Brand Names

  • Elicuis
    Bristol-Myers Squibb, Mexico
  • Eliquis
    Bristol Myers Squibb, Chile; Bristol Myers Squibb, Spain; Bristol-Myers Squibb, Australia; Bristol-Myers Squibb, Belgium; Bristol-Myers Squibb, Canada; Bristol-Myers Squibb, Switzerland; Bristol-Myers Squibb, Czech Republic; Bristol-Myers Squibb, Germany; Bristol-Myers Squibb, Denmark; Bristol-Myers Squibb, France; Bristol-Myers Squibb, Georgia; Bristol-Myers Squibb, Hungary; Bristol-Myers Squibb, Ireland; Bristol-Myers Squibb, Israel; Bristol-Myers Squibb, Iceland; Bristol-Myers Squibb, Italy; Bristol-Myers Squibb, Japan; Bristol-Myers Squibb, Norway; Bristol-Myers Squibb, Poland; Bristol-Myers Squibb, Portugal; Bristol-Myers Squibb, Romania; Bristol-Myers Squibb, Russian Federation; Bristol-Myers Squibb, Sweden; Bristol-Myers Squibb, Singapore; Bristol-Myers Squibb, Slovenia; Bristol-Myers Squibb, Slovakia; Bristol-Myers Squibb, Thailand; Bristol-Myers Squibb, United States; Bristol-Myers Squibb Pharma Eeig UK, Cyprus; Bristol-Myers Squibb/Pfizer, Austria; Bristol-Myers Squibb/Pfizer, United Kingdom; Pfizer, Canada; Pfizer, Germany; Pfizer, Hong Kong; Pfizer, Croatia (Hrvatska); Pfizer, Indonesia; Pfizer, Malaysia; Pfizer, New Zealand; Pfizer Luxembourg, Bosnia & Herzegowina


BANBritish Approved Name
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.